Practical Evidence and Reflection on Hypertension Control Strategies in Stroke Prevention and Management in China

doi:10.12114/j.issn.1007-9572.2025.0183

Chinese General Practice ›› 2025, Vol. 28 ›› Issue (29): 3601-3607.DOI: 10.12114/j.issn.1007-9572.2025.0183

• Commentary • Previous Articles Next Articles

Practical Evidence and Reflection on Hypertension Control Strategies in Stroke Prevention and Management in China

1. Department of Neuroepidemiology, Beijing Neurosurgical Institute, Beijing 100070, China
2. Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China
3. Beijing Municipal Key Laboratory of Clinical Epidemiology, Beijing 100070, China

Received:2025-06-10 Revised:2025-07-15 Published:2025-10-15 Online:2025-08-26
Contact: JIANG Bin

高血压控制策略在中国卒中预防和管理中的应用与思考

1．100070　北京市神经外科研究所神经流行病学室
2．100070　北京市，首都医科大学附属北京天坛医院
3．100070　北京市，临床流行病学北京市重点实验室

通讯作者: 江滨

作者简介:

【专家简介】　江滨，研究员，主任医师，北京市神经外科研究所神经流行病学室副主任。中国高血压联盟理事，中国卒中学会高血压预防与管理分会常委兼秘书长，中国卒中学会脑血管病高危人群管理分会委员，中华预防医学会卒中预防与控制专业委员会委员。主要从事神经流行病学和社区人群脑卒中防治研究，近30年先后参加和主持完成的国家级或省部级的课题十余项，先后发表文章100余篇，其中SCI文章20余篇；参与多部指南、专家共识及专著部分章节编写；合著科普书一部；曾荣获2014年北京市科学技术奖一等奖（列第10名）。曾先后担任Stroke、Frontiers in Neurology、《中国全科医学》《中国卒中杂志》《中国脑血管病杂志》《国际脑血管病杂志》《中国慢性病预防与控制》等国内外杂志编委及审稿人。

作者贡献：

孙海欣负责资料收集和论文起草，最终版论文修订；江滨提出了文章主要观点，负责论文修改、审核；孙海欣、江滨对论文整体负责。

基金资助:
北京市神经外科研究所创新基金项目(2023所创新1)

Abstract

Abstract:

Hypertension is the primary cause of both death from stroke and the increased DALY burden of stroke. As the most important modifiable risk factor, the effective prevention and control of hypertension has become the core task of primary and secondary prevention of stroke. In February 2025, the World Stroke Organization and the World Hypertension League released the 2025 WSO/WHL Position Statement: Application of Hypertension Control Strategies in Stroke Prevention and Management. Based on the strategies and recommendations of the statement, this paper analyzes and interprets the practical evidence in the prevention and control of hypertension in China, and gives thoughts on constructing a hypertension prevention and control path with Chinese characteristics, aiming to provide reference for future applications and research of stroke prevention and management in China.

Key words: Stroke, Hypertension prevention and control, Policy-driven, Digital intelligence technology, National health literacy

摘要：

高血压是造成卒中死亡和增加卒中伤残调整寿命年（DALY）负担的首要原因。作为最重要的可调控危险因素，有效防控高血压已成为卒中一级和二级预防的核心任务。世界卒中组织（WSO）与世界高血压联盟（WHL）在2025年2月发布了《2025 WSO/WHL立场声明：高血压控制策略在卒中预防和管理中的应用》。基于该声明的策略和建议，本文对中国在高血压防控工作中的实践证据进行分析和解读，同时提出构建具有中国特色高血压防控路径的思考，旨在为未来中国卒中预防和管理的相关应用和研究提供参考。

关键词: 卒中, 高血压防控, 政策驱动, 数智技术, 全民健康素养

CLC Number:

R 743

SUN Haixin,JIANG Bin. Practical Evidence and Reflection on Hypertension Control Strategies in Stroke Prevention and Management in China[J]. Chinese General Practice, 2025, 28(29): 3601-3607. DOI: 10.12114/j.issn.1007-9572.2025.0183.
孙海欣,江滨. 高血压控制策略在中国卒中预防和管理中的应用与思考[J]. 中国全科医学, 2025, 28(29): 3601-3607. DOI: 10.12114/j.issn.1007-9572.2025.0183.

References 50

[20]	WANG W Z, JIANG B, WU S P，et al. Change in stroke incidence from a population-based intervention trial in three urban communities in China[J]. Neuroepidemiology，2007,28(3):155-161. DOI：10.1159/000103268.
[21]	JIANG B, WANG W Z, WU S P，et al. Effects of urban community intervention on 3-year survival and recurrence after first-ever stroke[J]. Stroke，2004,35(6):1242-1247. DOI：10.1161/01.STR.0000128417.88694.9f.
[22]	王文志，吴升平，洪震，等. 社区人群脑卒中危险因素综合干预研究[J]. 医学研究通讯，2002,31(1):12-16. DOI：10.3969/j.issn.1673-548X.2002.01.003.
[23]	SUN Y X, MU J J, WANG D W，et al. A village doctor-led multifaceted intervention for blood pressure control in rural China：an open，cluster randomised trial[J]. Lancet，2022,399(10339):1964-1975. DOI：10.1016/S0140-6736(22)00325-7.
[24]	HE J, OUYANG N X, GUO X F，et al. Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease（CRHCP）：an open-label，blinded-endpoint，cluster-randomised trial[J]. Lancet，2023,401(10380):928-938. DOI：10.1016/S0140-6736(22)02603-4.
[25]	GUO X F, OUYANG N X, SUN G Z，et al. Multifaceted intensive blood pressure control model in older and younger individuals with hypertension：arandomized clinical trial[J]. JAMA Cardiol，2024,9(9):781-790. DOI：10.1001/jamacardio.2024.1449.
[26]	CASTELLANOJ M, POCOCKS J, BHATTD L，et al. Polypill strategy in secondary cardiovascular prevention[J]. N Engl J Med，2022,387(11):967-977. DOI：10.1056/NEJMoa2208275.
[27]	ROSHANDEL G, KHOSHNIA M, POUSTCHI H，et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases（PolyIran）：a pragmatic，cluster-randomised trial[J]. Lancet，2019,394(10199):672-683. DOI：10.1016/S0140-6736(19)31791-X.
[28]	YANL L, GONG E Y, GU W B，et al. Effectiveness of a primary care-based integrated mobile health intervention for stroke management in rural China（SINEMA）：a cluster-randomized controlled trial[J]. PLoS Med，2021,18(4):e1003582. DOI：10.1371/journal.pmed.1003582.
[1]	GBD 2019 Stroke Collaborators. Global，regional，and national burden of stroke and its risk factors，1990-2019：a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet Neurol，2021,20(10):795-820. DOI：10.1016/S1474-4422(21)00252-0.
[2]	SAINI V, GUADA L, YAVAGALD R. Global epidemiology of stroke and access to acute ischemic stroke interventions[J]. Neurology，2021,97(20 Suppl 2):S6-16. DOI：10.1212/WNL.0000000000012781.
[3]	FEIGINV L, LAWESC M, BENNETTDA，et al. Worldwide stroke incidence and early case fatality reported in 56 population-based studies：a systematic review[J]. Lancet Neurol，2009,8(4):355-369. DOI：10.1016/S1474-4422(09)70025-0.
[4]	JIANG B. Current snapshots on stroke prevention and control and more proactive national strategies against it in China[J]. J Cent Nerv Syst Dis，2025,17:11795735251337605. DOI：10.1177/11795735251337605.
[5]	GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories，1990-2019：a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet，2020,396(10258):1223-1249. DOI：10.1016/S0140-6736(20)30752-2.
[6]	WHELTONS P, MCEVOYJ W, SHAW L，et al. Association of normal systolic blood pressure level with cardiovascular disease in the absence of risk factors[J]. JAMA Cardiol，2020,5(9):1011-1018. DOI：10.1001/jamacardio.2020.1731.
[7]	RAPSOMANIKI E, TIMMIS A, GEORGE J，et al. Blood pressure and incidence of twelve cardiovascular diseases：lifetime risks，healthy life-years lost，and age-specific associations in 1.25 million people[J]. Lancet，2014,383(9932):1899-1911. DOI：10.1016/S0140-6736(14)60685-1.
[8]	LEWINGTON S, CLARKE R, QIZILBASH N，et al. Age-specific relevance of usual blood pressure to vascular mortality：a meta-analysis of individual data for one million adults in 61 prospective studies[J]. Lancet，2002,360(9349):1903-1913. DOI：10.1016/s0140-6736(02)11911-8.
[9]	PANDIANJ D, SYLAJAP N, LACKLANDD T，et al. World Stroke Organization and World Hypertension League position statement on hypertension control strategies in prevention and management of stroke[J]. Int J Stroke，2025,20(2):151-165. DOI：10.1177/17474930241309276.
[10]	WANG W Z, JIANG B, SUN H X，et al. Prevalence，incidence，and mortality of stroke in China：results from a nationwide population-based survey of 480 687 adults[J]. Circulation，2017,135(8):759-771. DOI：10.1161/CIRCULATIONAHA.116.025250.
[29]	赵洁，常红，李佩佩，等. 可穿戴设备在脑卒中危险因素监测及风险预测中的研究进展[J]. 中华护理杂志，2022,57(9):1141-1146.
[30]	周腾，白璐，陈轶戈，等. 人工智能驱动下的脑卒中高危人群早期筛查和预防工作模式研究[J]. 中国医药导报，2019,16(11):165-168,181.
[31]	World Health Organation. HEARTS：technical package for cardiovascular disease management in primary health care：Risk-based CVD management[EB/OL]. （2020-07-13）[2025-05-14].
[32]	ZHANG X H, GUAN T R, WANG H，et al. S-21-1：implementing hearts hypertension control project in China[J]. J Hypertens，2023,41(Suppl 1):e51. DOI：10.1097/01.hjh.0000913208.74263.8d.
[33]	健康中国行动促进委员会.健康中国行动计划（2019-2030年）[EB/OL].（2019-07-09）[2021-07-14].
[34]	沈寅飞，余蕊. 减盐行动"落地生根"我国居民减盐健康指数持续提升[J]. 中国盐业，2024(18):18-19. DOI：10.19396/j.cnki.issn1004-9169.2024.18.002.
[35]	国家基层高血压防治管理指南[J]. 中国循环杂志，2017,32(11):1041-1048.
[36]	国家基层高血压防治管理指南2020版[J]. 中国循环杂志，2021,36(3):209-220.
[37]	尤莉莉，赵金红，陈新月，等. 国家基本公共卫生服务项目十年评价（2009—2019年）系列报告（二）——国家基本公共卫生服务项目实施十年的进展与成效[J]. 中国全科医学，2022,25(26):3209-3220. DOI：10.12114/j.issn.1007-9572.2022.0407.
[38]	尤莉莉，刘远立. 国家基本公共卫生服务项目十年评价（2009—2019年）系列报告（一）——实施国家基本公共卫生服务项目的意义和经验[J]. 中国全科医学，2022,25(26):3203-3208. DOI：10.12114/j.issn.1007-9572.2022.0441.
[39]	SHEIKH S, SINHAA D, AGARWAL R. Home blood pressure monitoring：how good a predictor of long-term risk?[J]. Curr Hypertens Rep，2011,13(3):192-199. DOI：10.1007/s11906-011-0193-z.
[40]	LIU F D, SHEN X L, ZHAO R，et al. Pulse pressure as an independent predictor of stroke：a systematic review and a meta-analysis[J]. Clin Res Cardiol，2016,105(8):677-686. DOI：10.1007/s00392-016-0972-2.
[41]	吴雅婷，魏宸铭，桑振华，等. 可穿戴设备在卒中风险预测及卒中后管理中的应用进展[J]. 中国卒中杂志，2025,20(1):55-62.
[42]	SILVAG S, SCHWAMML H. Advances in stroke：digital health[J]. Stroke，2021,52(1):351-355. DOI：10.1161/strokeaha.120.033239.
[11]	WANG J H, BAI L L, SHI M，et al. Trends in age of first-ever stroke following increased incidence and life expectancy in a low-income Chinese population[J]. Stroke，2016,47(4):929-935. DOI：10.1161/STROKEAHA.115.012466.
[12]	SUN H X, GE S Q, JIANG B，et al. Incidence of first-ever stroke，stroke events，and early case fatality rate in China：results from a national population-based survey[J]. Neuroepidemiology，2025:1-13. DOI：10.1159/000543474.
[13]	WANG W Z, WANG D, LIU H M，et al. Trend of declining stroke mortality in China：reasons and analysis[J]. Stroke Vasc Neurol，2017,2(3):132-139. DOI：10.1136/svn-2017-000098.
[14]	MA Q F, LI R, WANG L J，et al. Temporal trend and attributable risk factors of stroke burden in China，1990-2019：an analysis for the Global Burden of Disease Study 2019[J]. Lancet Public Health，2021,6(12):e897-906. DOI：10.1016/S2468-2667(21)00228-0.
[15]	张梅，吴静，张笑，等. 2018年中国成年居民高血压患病与控制状况研究[J]. 中华流行病学杂志，2021,42(10):1780-1789. DOI：10.3760/cma.j.cn112338-20210508-00379.
[16]	NCD Risk Factor Collaboration （NCD-RisC）. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019：a pooled analysis of 1201 population-representative studies with 104 million participants[J]. Lancet，2021,398(10304):957-980. DOI：10.1016/S0140-6736(21)01330-1.
[17]	CHEN J Y, ZHU Q R, YU L L，et al. Stroke risk factors of stroke patients in China：anationwide community-based cross-sectional study[J]. Int J Environ Res Public Health，2022,19(8):4807. DOI：10.3390/ijerph19084807.
[18]	XU A Q, MA J X, GUO X L，et al. Association of a province-wide intervention with salt intake and hypertension in Shandong Province，China，2011-2016[J]. JAMA Intern Med，2020,180(6):877-886. DOI：10.1001/jamainternmed.2020.0904.
[19]	NEAL B, WU Y F, FENG X X，et al. Effect of salt substitution on cardiovascular events and death[J]. N Engl J Med，2021,385(12):1067-1077. DOI：10.1056/NEJMoa2105675.
[43]	MCMANUSR J, LITTLE P, STUART B，et al. Home and Online Management and Evaluation of Blood Pressure（HOME BP）using a digital intervention in poorly controlled hypertension：randomised controlled trial[J]. BMJ，2021,372:m4858. DOI：10.1136/bmj.m4858.
[44]	CHANDLER J, SOX L, DIAZ V，et al. Impact of 12-month smartphone breathing meditation program upon systolic blood pressure among non-medicated stage 1 hypertensive adults[J]. Int J Environ Res Public Health，2020,17(6):1955. DOI：10.3390/ijerph17061955.
[45]	徐琢，李江津，王婧，等. 移动互联网对在职高血压患者自我管理的影响研究[J]. 中国全科医学，2017,20(S2):242-244.
[46]	刘政，王锡榜，周艳红，等. 互联网+医生的社区高血压患者慢病管理模式效果[J]. 解放军医院管理杂志，2020,27(2):156-161. DOI：10.16770/J.cnki.1008-9985.2020.02.017.
[47]	骆青林，陈洪，刘丽萍，等. APP在"H"型高血压出院患者延续护理中的应用价值[J]. 慢性病学杂志，2018,19(5):647-649. DOI：10.16440/j.cnki.1674-8166.2018.05.037.
[48]	MCMANUS R J, MANT J, HAQUE M S，et al. Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease：the TASMIN-SR randomized clinical trial[J]. JAMA，2014,312(8):799-808. DOI：10.1001/jama.2014.10057.
[49]	ZHANG X Y, WANG S M, ZHOU X Y，et al. A village doctor-led mobile health intervention for cardiovascular risk reduction in rural China：cluster randomised controlled trial[J]. BMJ，2025,389:e082765. DOI：10.1136/bmj-2024-082765.
[50]	中国互联网络信息中心. 第55次《中国互联网络发展状况统计报告》[EB/OL].（2025-01-17）[2025-05-17].

Practical Evidence and Reflection on Hypertension Control Strategies in Stroke Prevention and Management in China

高血压控制策略在中国卒中预防和管理中的应用与思考

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References 50

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	HAN Xue, LIU Huan, LOU Xiaole, SONG Jianing, ZHANG Ziang, GENG Zongxiao, WANG Shan, ZHANG Yongqing, XU Lei. Intermittent θ Burst Stimulation Combined with Chin Tuck Against Resistance Training for Dysphagia in Stroke Patients: a Randomized Controlled Trial [J]. Chinese General Practice, 2025, 28(29): 3625-3630.
[2]	SU Qing, XU Yao, LI Yihang, WANG Liyan, CAI Yefeng, NI Xiaojia. Quality Evaluation of Methodology on the Changes in Traditional Chinese Medicine Syndromes of Stroke and Risk Population [J]. Chinese General Practice, 2025, 28(29): 3694-3702.
[3]	LI Yibing, JIA Hongbo, FAN Xiaonong, ZHAO Wenjun, LIU Wei, GE Wenyi, LI Songjiao, LEI Kangchen, ZHANG Menglong, ZHANG Weiwei, CHEN Yang, LI Li. Comprehensive Evaluation of Prognostic Factors Affecting Dysphagia after Stroke: an Umbrella Review [J]. Chinese General Practice, 2025, 28(29): 3631-3637.
[4]	YANG Ji, ZHANG Yao, ZHAO Yingqiang, ZHANG Qiuyue. Evaluation of the Effectiveness of TCM Three-level Prevention and Control Model in the Management of Patients with Coronary Heart Disease and Stroke: a Single-center, Prospective Cohort Study [J]. Chinese General Practice, 2025, 28(22): 2750-2761.
[5]	TAN Yi, ZHU Lihong, YIN Zengwei, HOU Shunan, YU Houming. A Real-world Study of MRI-guided Intravenous Thrombolytic Therapy in Acute Ischemic Stroke [J]. Chinese General Practice, 2025, 28(20): 2508-2515.
[6]	CHU Tianyu, GU Yan. Carotid Artery Calcification Features in Plaque Stability and Clinical Events [J]. Chinese General Practice, 2025, 28(18): 2247-2252.
[7]	TAN Wenbin, LI Jia, LIU Mingyu, LU Yongxin, CHENG Yaxin. Research Progress on the Influence of Nervous System Diseases and Related Therapeutic Drugs on Osteoporosis [J]. Chinese General Practice, 2025, 28(17): 2092-2100.
[8]	LI Mei, JIANG Dongsheng, ZHAO Jingjing, CAO Yajing, ZHANG Fan, TANG Lijuan, LIU Xiaoli. Correlation Analysis of Homocysteine and Stroke in People over 40 Years Old [J]. Chinese General Practice, 2025, 28(14): 1723-1729.
[9]	ZHAO Zhixin, MEI Yongxia, WANG Xiaoxuan, JIANG Hu, WANG Wenna, ZHANG Zhenxiang. Cognition and Experience of Social Participation in Stroke Survivors: a Meta-synthesis Based on Qualitative Studies [J]. Chinese General Practice, 2025, 28(10): 1273-1280.
[10]	LIU Zuting, XU Minghuan, YANG Xuezhi, MO Jiali, LIU Xingyu, DU Huijie, ZHANG Huiqin, YI Yingping, KUANG Jie. Correlation between the Systemic Inflammatory Response Index and Risk of Ischemic Stroke Recurrence [J]. Chinese General Practice, 2025, 28(05): 541-547.
[11]	DU Huijie, LIU Xingyu, XU Minghuan, YANG Xuezhi, ZHANG Huiqin, MO Jiali, LU Yi, KUANG Jie. Advances in the Prognostic Prediction of Acute Ischemic Stroke: Using Machine Learning Predictive Models as an Example [J]. Chinese General Practice, 2025, 28(05): 554-560.
[12]	ZHANG Pingshu, XUE Jing, XING Aijun, WANG Lianhui, MA Qian, FU Yongshan, YUAN Xiaodong. Study on Sleep Status and Prognostic Factors in Patients with Acute Posterior Circulation Ischemic Stroke [J]. Chinese General Practice, 2025, 28(05): 548-553.
[13]	ZHOU Chenxi, LIN Beilei, TANG Shangfeng, ZHANG Zhenxiang, WANG Xiaoxuan, JIANG Hu, ZHANG Dudu, LIU Bowen, LI Xin. Construction of Conceptual Framework of Proactive Health Behavior in Stroke Patients [J]. Chinese General Practice, 2025, 28(05): 534-540.
[14]	NI Xiaojia, LIN Hao, LUO Xufei, KUANG Zhuoran, LIU Yunlan, GUO Jianwen, CHEN Yaolong, CAI Yefeng, Working Group of Clinical Practice Guideline for the Prevention and Treatment of Stroke with Integrated Traditional Chinese and Western Medicine. Clinical Practice Guideline for the Prevention and Treatment of Stroke with Integrated Traditional Chinese and Western Medicine (2023 Edition) [J]. Chinese General Practice, 2025, 28(05): 521-533.
[15]	YUAN Dan, WANG Ying, WANG Yingpeng, XU Li, XUE Jia, CHENG Jingjing, WANG Haipeng. Effect of the Remote Ischemic Postconditioning on the Prognosis of Patients with Acute Ischemic Stroke beyond Time Window: a Randomized Controlled Trial [J]. Chinese General Practice, 2025, 28(02): 169-174.